EASE™ expands to Italy with first study procedures evaluating EndoZip™ for Automated Gastric Remodeling
CAESAREA, Israel, Sept. 15, 2026 /PRNewswire/ -- Nitinotes Ltd., developer of the EndoZip™ Automated Suturing System for Endoscopic Sleeve Gastroplasty (ESG), today announced the completion of the first EASE™ clinical trial procedures at Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy.
Gemelli has been performing commercial EndoZip™ procedures following the system's CE Mark approval and is now participating as a clinical site in the EASE™ study, which is evaluating EndoZip™ in support of Nitinotes' U.S. regulatory pathway.
The procedures were performed by Prof. Ivo Boskoski, MD, PhD, Associate Professor of Gastroenterology & Digestive Endoscopy at Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
The EASE™ study is evaluating the safety and effectiveness of EndoZip™ for Endoscopic Sleeve Gastroplasty, a minimally invasive procedure for the treatment of obesity. EndoZip™ brings automation to gastric remodeling through a single-operator workflow designed to reduce the technical complexity of conventional manual endoscopic suturing and support a more standardized approach to procedure execution.
"As a research hospital, advancing new treatment approaches and providing patients access to innovative technologies are important parts of our mission," said Prof. Boskoski. "We are pleased to participate in the EASE™ clinical trial and contribute to the continued evolution of endobariatric care."
"The first EASE™ procedures at Gemelli represent important progress in the clinical development of EndoZip™," said Lloyd Diamond, Chief Executive Officer of Nitinotes. "Prof. Boskoski and the team at Gemelli bring extensive expertise in advanced endoscopy, and their participation in EASE™ will contribute to the growing body of clinical evidence supporting Automated Gastric Remodeling and its potential role in the evolving obesity treatment continuum between pharmacotherapy and bariatric surgery."
Nitinotes also recognizes Prof. Cristiano Spada and Dr. Vincenzo Bove for their participation and valuable contributions, as well as the broader clinical team at Fondazione Policlinico Universitario Agostino Gemelli IRCCS for their collaboration and support.
About Nitinotes
Nitinotes is a privately held medical device company pioneering automated endoluminal suturing technologies for the treatment of obesity. The company's flagship system, EndoZip™, is an automated ESG platform designed to support a standardized approach to gastric remodeling. EndoZip™ received CE Mark approval in November 2025 and is commercially available in the European Union and other CE Mark–accepting markets.
For more information, visit https://nitinotesurgical.com.
Media Contact:
Offer Nonhoff
Chief Financial Officer
offer@nitinotesurgical.com
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/nitinotes-announces-first-ease-clinical-trial-procedures-at-fondazione-policlinico-universitario-agostino-gemelli-irccs-in-italy-302878217.html
Die an der Schweizer Börse SIX kotierte EEII AG hat für das erste Halbjahr 2026 einen Verlust von 547’568 Franken ausgewiesen. Bereits im zweiten Halbjahr 2025 hatte die Gesellschaft einen Fehlbetrag von 332’306 Franken verbucht. Der Nettoinventarwert (NAV) der EEII-Aktien lag per 30. Juni...
Nach dem nächtlichen Grossbrand an der Ruessenstrasse in Baar im Kanton Zug gehen die Strafuntersuchungsbehörden von vorsätzlicher Brandlegung aus. Mehrere Fahrzeuge waren am späten Abend des 28. September in Flammen aufgegangen und vollständig ausgebrannt. Die Ermittler stufen Brandstiftung...
Mit einem betont unterhaltsamen und zugleich programmatischen Auftritt hat der Kanton Schwyz seine Rolle als Gastkanton an der 83. Olma in St. Gallen übernommen. Bereits die offizielle Eröffnungsfeier im Theater St. Gallen zeigte, wie breit sich der Innerschweizer Kanton präsentieren will –...
Inflationssorgen und steigende Ölpreise haben Europas wichtigste Aktienmärkte zur Wochenmitte spürbar belastet und zugleich die Monatsbilanz eingetrübt. Der EuroStoxx 50 schloss am Mittwoch 0,81 Prozent tiefer bei 6269,02 Punkten. Im Monatsverlauf verlor der Leitindex der Eurozone 2,4 Prozent...
Das Schweizer Studio Urban Games bringt seine erfolgreiche Verkehrssimulation in die nächste Runde: Transport Fever 3 ist ab sofort erhältlich – erstmals auch in einer Version für macOS. Spielerinnen und Spieler bauen darin über mehr als 125 Jahre Transportgeschichte hinweg ein eigenes...
